Citation Impact
Citing Papers
Infrared molecular fingerprinting of blood-based liquid biopsies for the detection of cancer
2021 StandoutNobel
ADAPT: An Algorithm Incorporating PRO‐C3 Accurately Identifies Patients With NAFLD and Advanced Fibrosis
2018
Oral diseases: a global public health challenge
2019 Standout
Ferroptosis: molecular mechanisms and health implications
2020 Standout
Head and neck squamous cell carcinoma
2020 Standout
Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
2024 Standout
Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
2018 Standout
Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries
2021 Standout
Inhibition of Class-3 aldehyde dehydrogenase and cell growth by restored lipid peroxidation in hepatoma cell lines
1999
NAFLD as a driver of chronic kidney disease
2020
AGA Clinical Practice Update: Diagnosis and Management of Nonalcoholic Fatty Liver Disease in Lean Individuals: Expert Review
2022
Obesity and nonalcoholic fatty liver disease: From pathophysiology to therapeutics
2018
Chronic inflammation in the etiology of disease across the life span
2019 Standout
4-Hydroxynonenal and PPARγ ligands affect proliferation, differentiation, and apoptosis in colon cancer cells
2007
Childhood predictors of adult fatty liver. The Cardiovascular Risk in Young Finns Study
2016
Pancreatic cancer
2020 Standout
Burden of liver diseases in the world
2018 Standout
Targeting Ferroptosis to Iron Out Cancer
2019 Standout
Clinical development and potential of photothermal and photodynamic therapies for cancer
2020 Standout
4-Hydroxynonenal inhibits telomerase activity and hTERT expression in human leukemic cell lines
2006
Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention
2017 Standout
Hallmarks of aging: An expanding universe
2023 Standout
American Association of Clinical Endocrinology Clinical Practice Guideline for the Diagnosis and Management of Nonalcoholic Fatty Liver Disease in Primary Care and Endocrinology Clinical Settings
2022
Global prevalence, incidence, and outcomes of non-obese or lean non-alcoholic fatty liver disease: a systematic review and meta-analysis
2020
Modulation of oxidative stress as an anticancer strategy
2013 Standout
4-Hydroxynonenal modulation of p53 family gene expression in the SK-N-BE neuroblastoma cell line
2004
The role of macrophages in nonalcoholic fatty liver disease and nonalcoholic steatohepatitis
2018
Genome-Scale CRISPR-Mediated Control of Gene Repression and Activation
2014 Standout
Nasopharyngeal carcinoma
2019 Standout
Hepatocellular carcinoma
2021 Standout
Hydroxyalkenals and oxidized phospholipids modulation of endothelial cytoskeleton, focal adhesion and adherens junction proteins in regulating endothelial barrier function
2011
Prevalence of coeliac disease in Down's syndrome
2001
NAFLD and diabetes mellitus
2016
Metabolic Inflammation-Associated IL-17A Causes Non-alcoholic Steatohepatitis and Hepatocellular Carcinoma
2016
Increased Oxygen Desaturation Time During Sleep Is a Risk Factor for NASH in Patients With Obstructive Sleep Apnea: A Prospective Cohort Study
2022
Cause, Pathogenesis, and Treatment of Nonalcoholic Steatohepatitis
2017
Colorectal cancer
2019 Standout
Mechanisms of NAFLD development and therapeutic strategies
2018 Standout
Risk factors for nonalcoholic fatty liver disease after gastrectomy for gastric cancer
2019
Preclinical Models for Studying NASH-Driven HCC: How Useful Are They?
2018
Sex and gender: modifiers of health, disease, and medicine
2020 Standout
Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
2010 Standout
Reactive oxygen species (ROS) as pleiotropic physiological signalling agents
2020 Standout
Role of reactive aldehyde in cardiovascular diseases
2000
Metabolic risk factors and incident advanced liver disease in non-alcoholic fatty liver disease (NAFLD): A systematic review and meta-analysis of population-based observational studies
2020
Effect of tirzepatide versus insulin degludec on liver fat content and abdominal adipose tissue in people with type 2 diabetes (SURPASS-3 MRI): a substudy of the randomised, open-label, parallel-group, phase 3 SURPASS-3 trial
2022
Non-alcoholic fatty liver disease
2021 Standout
Obesity and Cardiovascular Disease: A Scientific Statement From the American Heart Association
2021 Standout
Growth inhibition and differentiation induction in murine erythroleukemia cells by 4-hydroxynonenal
2001
Harnessing Muscle–Liver Crosstalk to Treat Nonalcoholic Steatohepatitis
2020
4-Hydroxynonenal, a lipid peroxidation product of dietary polyunsaturated fatty acids, has anticarcinogenic properties in colon carcinoma cell lines through the inhibition of telomerase activity
2009
Real-world data reveal a diagnostic gap in non-alcoholic fatty liver disease
2018
Glycogen synthase kinase 3β inhibitors prevent hepatitis C virus release/assembly through perturbation of lipid metabolism
2017 StandoutNobel
Leveraging Human Genetics to Identify Potential New Treatments for Fatty Liver Disease
2020
Assessment of lipid peroxidation by measuring malondialdehyde (MDA) and relatives in biological samples: Analytical and biological challenges
2016 Standout
Genetic Factors That Affect Risk of Alcoholic and Nonalcoholic Fatty Liver Disease
2016
4-hydroxynonenal and regulation of cell cycle: effects on the pRb/E2F pathway
2004
Hypertension, diabetes, atherosclerosis and NASH: Cause or consequence?
2017
Dissociation of Adaptive Thermogenesis from Glucose Homeostasis in Microbiome-Deficient Mice
2020
Gastric cancer
2020 Standout
Defining roles of specific reactive oxygen species (ROS) in cell biology and physiology
2022 Standout
Chronic hepatitis C virus infection and lipoprotein metabolism
2015
4-Hydroxynonenal affects pRb/E2F pathway in HL-60 human leukemic cells
2002
Genetics and epigenetics of NAFLD and NASH: Clinical impact
2017
TM6SF2 rs58542926 influences hepatic fibrosis progression in patients with non-alcoholic fatty liver disease
2014
Down's syndrome
2003 Standout
The biology and therapy of adult acute lymphoblastic leukemia
2003
Effect of 4-hydroxynonenal on cell cycle progression and expression of differentiation-associated antigens in HL-60 cells
1996
Macrophages in obesity and non-alcoholic fatty liver disease: Crosstalk with metabolism
2019
Candidate rejuvenating factor GDF11 and tissue fibrosis: friend or foe?
2020
Cervical cancer
2019 Standout
Inhibition of D1, D2, and a cyclin expression in HL-60 cells by the lipid peroxydation product 4-hydroxynonenal
1999
Inflammation in obesity, diabetes, and related disorders
2022 Standout
Hepatocellular carcinoma
2022 Standout
Gut microbiota in human metabolic health and disease
2020 Standout
Chronic intermittent hypoxia contributes to non-alcoholic steatohepatitis progression in patients with obesity
2022
AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease
2023 Standout
NASH in Lean Individuals
2019
Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods
2018 Standout
The Genetics of Nonalcoholic Fatty Liver Disease: Spotlight on PNPLA3 and TM6SF2
2015
EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection
2017 Standout
Head and Neck Cancer
2020 Standout
Mechanisms of Insulin Action and Insulin Resistance
2018 Standout
Prevalence and Profile of Nonalcoholic Fatty Liver Disease in Lean Adults: Systematic Review and Meta‐Analysis
2020
Non-Alcoholic Fatty Liver Disease: Metabolic, Genetic, Epigenetic and Environmental Risk Factors
2021
PU.1 inhibits GATA-1 function and erythroid differentiation by blocking GATA-1 DNA binding
2000
The "Two-Faced" Effects of Reactive Oxygen Species and the Lipid Peroxidation Product 4-Hydroxynonenal in the Hallmarks of Cancer
2010
Defining Improvement in Nonalcoholic Steatohepatitis for Treatment Trial Endpoints: Recommendations From the Liver Forum
2019
Hepatitis B virus core‐related antigen as a surrogate marker for covalently closed circular DNA
2016
AISF position paper on nonalcoholic fatty liver disease (NAFLD): Updates and future directions
2017
Epidemiological modifiers of non-alcoholic fatty liver disease: Focus on high-risk groups
2015
Breast Cancer Treatment
2019 Standout
The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases
2017 Standout
TM6SF2: A Novel Genetic Player in Nonalcoholic Fatty Liver and Cardiovascular Disease
2021
Cancer statistics for the year 2020: An overview
2021 Standout
Cancer treatment and survivorship statistics, 2016
2016 Standout
The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review
2023 Standout
Global epidemiology of lean non‐alcoholic fatty liver disease: A systematic review and meta‐analysis
2020
Cancer treatment and survivorship statistics, 2019
2019 Standout
EASL Recommendations on Treatment of Hepatitis C 2018
2018 Standout
Reactive Oxygen Species in Metabolic and Inflammatory Signaling
2018 Standout
EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma
2018 Standout
Lipid Peroxidation: Production, Metabolism, and Signaling Mechanisms of Malondialdehyde and 4-Hydroxy-2-Nonenal
2014 Standout
Review article: the emerging role of genetics in precision medicine for patients with non‐alcoholic steatohepatitis
2020
Metabolic disturbances of non-alcoholic fatty liver resemble the alterations typical for type 2 diabetes
2017
Redox Signaling by Reactive Electrophiles and Oxidants
2018
Natural history of NASH and HCC
2020
Oxidative Stress and Lipid Peroxidation Products in Cancer Progression and Therapy
2012
Works of Chiara Rosso being referenced
Altered amino acid concentrations in NAFLD: Impact of obesity and insulin resistance
2017
Hypoxia‐inducible factor 2α drives nonalcoholic fatty liver progression by triggering hepatocyte release of histidine‐rich glycoprotein
2017
Myostatin regulates the fibrogenic phenotype of hepatic stellate cells via c-jun N-terminal kinase activation
2019
Glucokinase Regulatory Protein Gene Polymorphism Affects Liver Fibrosis in Non-Alcoholic Fatty Liver Disease
2014
Liver fibrosis: the 2017 state of art
2017
Prevalence and Risk Factors of Significant Fibrosis in Patients With Nonalcoholic Fatty Liver Without Steatohepatitis
2019
Renin-Angiotensin System Inhibitors, Type 2 Diabetes and Fibrosis Progression: An Observational Study in Patients with Nonalcoholic Fatty Liver Disease
2016
Inhibition of c-myc Expression Induced by 4-Hydroxynonenal, a Product of Lipid Peroxidation, in the HL-60 Human Leukemic Cell Line
1994
Crosstalk between adipose tissue insulin resistance and liver macrophages in non-alcoholic fatty liver disease
2019
Liver Cancer: Connections with Obesity, Fatty Liver, and Cirrhosis
2015
Peripheral insulin resistance predicts liver damage in nondiabetic subjects with nonalcoholic fatty liver disease
2015
2015
Chronic hepatitisC virus infection and lymphoproliferative disorders: Mixed cryoglobulinemia syndrome, monoclonal gammopathy of undetermined significance, andB ‐cell non‐H odgkin lymphoma
2014
Molecular biology to check patients treated for CML.
1989
Expression of GATA-1 mRNA in human myeloid leukemic cells.
1994
Hepatitis B core‐related antigen kinetics in chronic hepatitis B virus genotype D‐infected patients treated with nucleos(t)ide analogues or pegylated‐interferon‐α
2016
Lean NAFLD: A Distinct Entity Shaped by Differential Metabolic Adaptation
2019
Metabolic syndrome and severity of fibrosis in nonalcoholic fatty liver disease: An age‐dependent risk profiling study
2017
The macrophage activation marker sCD 163 is associated with morphological disease stages in patients with non‐alcoholic fatty liver disease
2016
[Diabetes, hypothyroidism and celiac disease in Down's syndrome. A case report].
1997
Non-Alcoholic Fatty Liver Disease and Extra-Hepatic Cancers
2016